A Phase 1 interventional study of BIA 2-093 and S-licarbazepine in Epilepsy, sponsored by Bial - Portela C S.A.. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Bial - Portela C S.A. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing eslicarbazepine in Epilepsy — none open to participants now, none under way, none of them phase 3. eslicarbazepine · Epilepsy.
Among the 45 studies testing eslicarbazepine in Epilepsy, this one is the 22nd largest by enrollment, is one of 3 that started in 2006, is one of 29 in phase 1, and was the 28th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →None of the 45 studies testing eslicarbazepine in Epilepsy is open now. The open studies under Epilepsy, anywhere →
eslicarbazepine: first FDA approval 2013 (APTIOM), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 32 across the 45 interventional studies. Of the 44 that completed or were terminated, 39 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 45 have an industry lead sponsor. The 2 most frequent:
Bial - Portela C S.A. is the lead sponsor of 136 studies on the registry; 1 is open to participants now.
44 studies in Epilepsy by Bial - Portela C S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 37 (84%) have results posted.
Among the 44 studies in Epilepsy by Bial - Portela C S.A., this one is the 20th largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2006, is one of 31 in phase 1, and was the 26th registered.
Bial - Portela C S.A.’s Epilepsy studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing eslicarbazepine in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bial - Portela C S.A.’s 44 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Single centre, open-label, randomised study in four parallel groups of healthy volunteers
Single centre, open-label, randomised study in four parallel groups of healthy volunteers: Group 1 = 900 mg of eslicarbazepine acetate (ESL, BIA 2-093); Group 2 = 450 mg of S-licarbazepine plus 450 mg of R-licarbazepine; Group 3 = 450 mg of S-licarbazepine; Group 4 = 450 mg of Rlicarbazepine. In each group, the study consisted of a single-dose period (Phase A) followed by a repeateddose period of 7 days of duration in which the investigational product was administered once daily (Phase B). The repeated-dose phase started 96 h post single-dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
900mg of eslicarbazepine acetate (ESL, BIA 2-093)
Drug: BIA 2-093
450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
Drug: S-licarbazepine · Drug: R-licarbazepine
450 mg of S-licarbazepine
Drug: S-licarbazepine
450 mg of Rlicarbazepine
Drug: R-licarbazepine
Tablets containing 900 mg
capsules containing 225 mg
capsules containing 225 mg
Cmax - the Maximum Plasma Concentration
BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.
Time frame: Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.
Tmax - the Time of Occurrence of Cmax
BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.
Time frame: Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.
AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity
BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.
Time frame: Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.
AUC0-t - the Area Under the Plasma Concentration-time Curve to Last Measurable Time Point
BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.
Time frame: Phase A: pre-dose (Day 1); and ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.Phase B: Days 6 to 10 inclusively: pre-dose. Day 11 (last dose): pre-dose; and ½, 1, 1½,2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose.
| Milestone | Eslicarbazepine Acetate | S-licarbazepine R-licarbazepine | S-licarbazepine | R-licarbazepine |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.
| ng/mL | Eslicarbazepine Acetate | S-licarbazepine R-licarbazepine | S-licarbazepine | R-licarbazepine |
|---|---|---|---|---|
| Cmax (BIA 2-194) | 15809 ± 3183 | 10496 ± 1432 | 10364 ± 3352 | 437 ± 143 |
| Cmax (BIA 2-195) | 222 ± 68.4 | 8099 ± 1258 | 132 ± 29.6 | 6941 ± 1054 |
| Cmax (Oxcarbazepine) | 136 ± 25.1 | 261 ± 53.5 | 92.8 ± 21.8 | 101 ± 28.6 |
BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.
| hours | Eslicarbazepine Acetate | S-licarbazepine R-licarbazepine | S-licarbazepine | R-licarbazepine |
|---|---|---|---|---|
| tmax (BIA 2-194) | 1.99 ± 0.916 | 1.01 ± 0.320 | 0.965 ± 0.496 | 10.7 ± 3.69 |
| tmax (BIA 2-195) | 18.6 ± 4.14 | 1.41 ± 0.320 | 11.7 ± 3.77 | 1.22 ± 0.582 |
| tmax (Oxcarbazepine) | 3.59 ± 1.61 | 1.34 ± 0.354 | 1.36 ± 1.44 | 1.21 ± 0.641 |
BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.
| ng.h/mL | Eslicarbazepine Acetate | S-licarbazepine R-licarbazepine | S-licarbazepine | R-licarbazepine |
|---|---|---|---|---|
| AUC0-∞ (BIA 2-194) | 271191 ± 47416 | 201409 ± 37377 | 132724 ± 20175 | 11003 ± 4476 |
| AUC0-∞ (BIA 2-195) | 8816 ± 2168 | 116884 ± 22425 | 5417 ± 824 | 66087 ± 16072 |
| AUC0-∞ (Oxcarbazepine) | 3181 ± 1078 | 4726 ± 1163 | 2500 ± 1923 | 1073 ± 793 |
BIA 2-194, BIA 2-195 and Oxcarbazepine are metabolites of BIA 2-093 and Licarbazepine.
| ng.h/mL | Eslicarbazepine Acetate | S-licarbazepine R-licarbazepine | S-licarbazepine | R-licarbazepine |
|---|---|---|---|---|
| AUC0-t (BIA 2-194) | 268045 ± 46861 | 198313 ± 38771 | 130147 ± 19326 | 9419 ± 4707 |
| AUC0-t (BIA 2-195) | 6757 ± 2211 | 114635 ± 21741 | 3074 ± 1001 | 65203 ± 16161 |
| AUC0-t (Oxcarbazepine) | 1947 ± 757 | 3401 ± 902 | 748 ± 308 | 422 ± 247 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eslicarbazepine Acetate | — | 0/8 (0%) | 6/8 (75%) |
| S-licarbazepine R-licarbazepine | — | 0/8 (0%) | 8/8 (100%) |
| S-licarbazepine | — | 0/8 (0%) | 4/8 (50%) |
| R-licarbazepine | — | 0/8 (0%) | 5/8 (62.5%) |
| Event | Eslicarbazepine Acetate | S-licarbazepine R-licarbazepine | S-licarbazepine | R-licarbazepine |
|---|---|---|---|---|
| TirednessGeneral disorders | 1/8 | 6/8 | 1/8 | 2/8 |
| HeadacheNervous system disorders | 3/8 | 3/8 | 1/8 | 1/8 |
| Paraesthesia lipsGastrointestinal disorders | 0/8 | 2/8 | 1/8 | 0/8 |
| DizzinessNervous system disorders | 2/8 | 0/8 | 0/8 | 0/8 |
| Burning sensation in eyeEye disorders | 1/8 | 0/8 | 0/8 | 0/8 |
| Visual disturbanceEye disorders | 0/8 | 0/8 | 0/8 | 1/8 |
| Dry mouthGastrointestinal disorders | 1/8 | 0/8 | 0/8 | 0/8 |
| NauseaGastrointestinal disorders | 1/8 | 0/8 | 0/8 | 0/8 |
| Numbness of tongueGastrointestinal disorders | 0/8 | 1/8 | 0/8 | 0/8 |
| Oral drynessGastrointestinal disorders | 0/8 | 1/8 | 0/8 | 1/8 |
| Age, Categorical(Participants) | Eslicarbazepine Acetate | S-licarbazepine R-licarbazepine | S-licarbazepine | R-licarbazepine | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 8 | 8 | 8 | 32 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Eslicarbazepine Acetate | S-licarbazepine R-licarbazepine | S-licarbazepine | R-licarbazepine | Total |
|---|---|---|---|---|---|
| Female | 4 | 4 | 4 | 4 | 16 |
| Male | 4 | 4 | 4 | 4 | 16 |
The record gives a start of Jun 2006, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 8 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eslicarbazepine